लोड हो रहा है...

Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial

Recurrence rate of hepatocellular carcinoma (HCC) is very high even after curative surgery, and no postoperative therapies have been definitively shown to prevent HCC recurrence. Sorafenib is proved to be effective for advanced HCC by two large randomized controlled trials in 2008 and 2009. Therefor...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:World J Hepatol
मुख्य लेखकों: Zhong, Jian-Hong, Du, Xue-Ke, Xiang, Bang-De, Li, Le-Qun
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Baishideng Publishing Group Inc 2016
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4990759/
https://ncbi.nlm.nih.gov/pubmed/27621761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v8.i23.957
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!